Evidence map›Paper›PMID 35661758›Full record

ArticleJournal of pharmaceutical sciences2022

Combining Machine Learning and Backgrounded Membrane Imaging: A Case Study in Comparing and Classifying Different Types of Biopharmaceutically Relevant Particles.

Christopher P Calderon, Ana Krhač Levačić, Constanze Helbig, Klaus Wuchner, Tim Menzen

Open access · hybridAbstract read
In one paragraph

Article in Journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Christopher P CalderonUrsa Analytics, Inc., Denver, CO 80212; Department of Chemical and Biological Engineering, University of Colorado Boulder, Boulder, Colorado 80303, United States. Electronic address: Chris.Calderon@UrsaAnalytics.com.
Ana Krhač LevačićCoriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany.
Constanze HelbigCoriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany.
Klaus WuchnerJanssen Research and Development, DPDS BTDS Analytical Development, Hochstr. 201, 8200 Schaffhausen, Switzerland.
Tim MenzenCoriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany. Electronic address: tim.menzen@coriolis-pharma.com.
Janssen (Switzerland) · CHPharmaplant (Germany) · DEUniversity of Colorado Boulder · US

Funding

Quantitative Biotherapeutic Particle Characterization via Deep Neural NetworksR41GM130513 · NIGMS · URSA ANALYTICS, INC. · PI CALDERON, CHRISTOPHER PETER, RANDOLPH, THEODORE W · 2018 to 2018
$222k
NIGMS NIH HHS R41 GM130513
6 · The paper itself

Abstract

This study investigates how backgrounded membrane imaging (BMI) can be used in combination with convolutional neural networks (CNNs) in order to quantitatively and qualitatively study subvisible particles in both protein biopharmaceuticals and samples containing synthetic model particles. BMI requires low sample volumes and avoids many technical complications associated with imaging particles in solution, e.g., air bubble interference, low refractive index contrast between solution and particles of interest, etc. Hence, BMI is an attractive technique for characterizing particles at various stages of drug product development. However, to date, the morphological information encoded in brightfield BMI images has scarcely been utilized. Here we show that CNN based methods can be useful in extracting morphological information from (label-free) brightfield BMI particle images. Images of particles from biopharmaceutical products and from laboratory prepared samples were analyzed with two types of CNN based approaches: traditional supervised classifiers and a recently proposed fingerprinting analysis method. We demonstrate that the CNN based methods are able to efficiently leverage BMI data to distinguish between particles comprised of different proteins, various fatty acids (representing polysorbate degradation related particles), and protein surrogates (NIST ETFE reference material) only based on BMI images. The utility of using the fingerprinting method for comparing morphological differences and similarities of particles formed in distinct drug products and/or laboratory prepared samples is further demonstrated and discussed through three case studies.

Indexed as

Biological ProductsPolysorbatesDrug DevelopmentMachine LearningNeural Networks, ComputerProteinsBiological ProductsPolysorbatesProteinsBiopharmaceutical characterizationImage analysisImaging methodsMicroparticle(s)Monoclonal antibody(s)MorphologyProtein aggregationProtein formulationSurfactant(s)

Identifiers

PMID35661758
PMCPMC9391316
OpenAlexW4282928606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.